Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$13.22 ▼ -0.29
(-2.15%)
MKT CAP: $776.6M • VOL: 439.9K
52W L $13 52W H $17
INMD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $370.5M | $394.8M | $492.0M |
| YoY Revenue Growth % | -6.2% | -19.8% | — |
| Gross Profit | $291.0M | $317.1M | — |
| Gross Margin % | 78.5% | 80.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $85.4M | $112.5M | $195.7M |
| Operating Margin % | 23.0% | 28.5% | 39.8% |
| Net Income (GAAP) | $0 | $0 | $197.9M |
| EBITDA (Normalized) | $86.2M | $113.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $85.3M | $132.7M | $176.8M |
| Capital Expenditures (CapEx) | $972.0K | $669.0K | — |
| Free Cash Flow (FCF) | $84.3M | $132.0M | $176.8M |
| FCF Margin % | 22.7% | 33.4% | 35.9% |
| Return on Invested Capital (ROIC %) | 17.7% | 16.2% | — |
| Cash & Short-Term Equivalents | $302.5M | $155.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $683.2M | $703.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR INMD.